CSTL – castle biosciences, inc. - common stock (US:NASDAQ)
Stock Stats
News
3/27
09:40 am
cstl
Low
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 [TheStreet.com]
3/27
09:05 am
cstl
Medium
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
3/23
09:17 pm
cstl
Low
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript [Seeking Alpha]
3/23
06:54 pm
cstl
Low
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk [Yahoo! Finance]
3/21
12:35 am
cstl
Medium
Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets [Yahoo! Finance]
2/26/2026
04:05 pm
cstl
-7.2%
BEAT
11/3/2025
04:07 pm
cstl
21.7%
BEAT
8/4/2025
04:05 pm
cstl
32.8%
BEAT
5/5/2025
04:06 pm
cstl
-10.7%
MISS
3/2
07:01 am
Upgrades
Buy
Morgan Stanley
Medium
-5.4%
3/2
07:01 am
Upgrades
Buy
Morgan Stanley
Medium
-5.4%
2/27
07:39 am
Maintains
Outperform
Outperform
Baird
Medium
-9.6%
2/27
07:39 am
Maintains
Outperform
Outperform
Baird
Medium
-9.6%
1/29
04:06 pm
Reiterates
Overweight
Overweight
KeyCorp
Low
0.6%
3/26
05:36 pm
cstl
Medium
Form 144 CASTLE BIOSCIENCES INC Filed by: MAETZOLD DEREK J
3/26
04:42 pm
cstl
Medium
Form SCHEDULE 13G/A CASTLE BIOSCIENCES INC Filed by: VANGUARD GROUP INC
3/19
04:21 pm
cstl
Low
Form 4 CASTLE BIOSCIENCES INC For: Mar 17 Filed by: MAETZOLD DEREK J
3/17
04:38 pm
cstl
Low
Form 4 CASTLE BIOSCIENCES INC For: Mar 13 Filed by: MAETZOLD DEREK J
3/16
04:08 pm
cstl
Low
Form 4 CASTLE BIOSCIENCES INC For: Mar 12 Filed by: Juvenal Tobin W
Show more
Top News Gainers
11/11 Q3/2019 9/30/2019 EPS 0.050 ZacksConsensus -0.310 ActVsEst 0.360 - Beat 19.6%
3/16 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 18.9%
8/22 Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019 14.1%
4/6 Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference 13.4%
10/29 Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting 11.0%
7/31 Form 4 CASTLE BIOSCIENCES INC For: Jul 29 Filed by: Cook Joseph C. III 10.9%
12/19 Form 8-K CASTLE BIOSCIENCES INC For: Dec 13 8.6%
10/31 Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk 8.4%
10/29 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
1/3 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.6%
Top News Decliners
3/11 Castle Biosciences (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $37.00 to $38.00. They now have an "outperform" rating on the stock. -12.7%
10/21 Castle Biosciences (NASDAQ: CSTL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.8%
9/6 Castle Biosciences (NASDAQ: CSTL) was given a new $33.00 price target on by analysts at Leerink Swann. They now have a "buy" rating on the stock. -11.5%
3/11 Castle Biosciences Inc (CSTL) Q4 2019 Earnings Call Transcript [The Motley Fool] -11.5%
2/25 Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 -9.4%
2/21 Form 4 CASTLE BIOSCIENCES INC For: Feb 19 Filed by: HealthQuest Venture Management, L.L.C. -7.4%
1/13 Castle Biosciences (NASDAQ: CSTL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock. -7.0%
9/3 Form 8-K CASTLE BIOSCIENCES INC For: Sep 03 -6.9%
10/18 Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node -5.7%
7/29 Form S-8 CASTLE BIOSCIENCES INC -5.3%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3